To describe the safety, tolerability and pharmacokinetics of PF-04447943 after administration of multiple, ascending, oral doses to healthy elderly subjects.
Additional Study Purpose Details: Phase I safety and pharmacokinetics study. Detailed Description: The study was terminated on 11/12/2008. There were no safety findings in this trial that resulted in the decision to terminate the trial. The study was closed in order to change the amount of drug that subjects would take and to shorten the number of days that the drug would be taken in a new study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
10
05 mg BID for 14 days
15 mg BID for 14 days
45mg BID for 14 days
Pfizer Investigational Site
Gainesville, Florida, United States
Primary Safety: Adverse events, change from baseline in vital signs, triplicate ECG, clinical safety laboratory endpoints
Time frame: 14 days
Pharmacokinetic endpoints will include plasma PF 04447943 AUCt, Cmax and Tmax
Time frame: 14 days
Changes in cognition from baseline
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo for 14 days